FBRX NASDAQ
Forte Biosciences, Inc.
1W: +61.1%
1M: +308.9%
3M: +178.7%
YTD: +224.0%
1Y: +611.6%
3Y: +200.0%
5Y: -90.7%
$76.65
+0.15 (+0.20%)
After Hours: $76.95 (+0.30, +0.39%)
Weekly Expected Move ±40.8%
$10
$32
$55
$77
$99
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range9.1-76.68
Volume2,524,608
Avg Volume499,895
Beta2.84
Dividend—
Analyst Ratings
Company Info
CEOPaul A. Wagner
Employees22
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-13
Websitefortebiorx.com
3060 Pegasus Park Drive
Dallas, TX 75247
US
Dallas, TX 75247
US
310 618 6994
About Forte Biosciences, Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Latest News
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug - Fierce Biotech
Biggest stock movers Monday: AVGO, FBRX, oil companies, and more
argenx strikes $2.2B deal for Forte Biosciences
Argenx to Buy Forte Biosciences for $2.2 Billion - WSJ
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Riley Antony A | M-Exempt | 375 | — | 2026-07-01 |
| Riley Antony A | F-InKind | 134 | $21.32 | 2026-07-01 |
| Riley Antony A | M-Exempt | 375 | — | 2026-07-01 |
| Wagner Paul A. | M-Exempt | 1,250 | — | 2026-07-01 |
| Wagner Paul A. | F-InKind | 98 | $21.32 | 2026-07-01 |